you are here: HomeNewsBusiness

India’s reputation as the world’s vaccine hub was surprisingly under the wraps

Now, as the Serum Institute of India reveals its massive production capabilities, countries queue up for the precious dose, giving New Delhi a chance at vaccine diplomacy

January 12, 2021 / 02:57 PM IST
Source: Reuters

Source: Reuters

The big story about COVID-19 vaccines is emerging now, belatedly. After the noise and news about Pfizer, AstraZeneca, Moderna and other global vaccine discoveries had quietened down, came a little-known fact, pleasantly enough, though, for India: The Serum Institute of India, founded over 50 years ago, is the world’s largest manufacturer of vaccines by volume. It is likely to provide not only most of the vaccines administered in India but elsewhere in the world, once exports are permitted later this year.

The upshot is that while wealthier countries will be looking - even slogging hard-to vaccinate their populations, low-income India will be holding the trump card. The existence of the world’s largest vaccine manufacturer helps to establish the basis for a domestic network of suppliers.

On January 11, the process of transporting Serum Institute’s Covishield vaccine began after the manufacturer had received the central government’s initial purchase order of 11 million (1.1 crore) doses at Rs 200 per dose.

This is how COVID-19 vaccines will travel from Pune, to across India

According to a research study conducted by Fitch Solutions, Asian economies are likely to run to three types in 2021. Countries that can possibly vaccinate most of their people in priority groups like their elderly population and extremely vulnerable health workers by June; those nations who can do so by September and a third group of economies that will take longer. India is happily placed in the first group, says the Fitch Solutions report.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Resultantly, India is, by a long shot, the lowest income group of countries in this first list, which has much more prosperous China, Malaysia, Singapore and Hong Kong in the pecking order.

So far, richer and developed countries are fretting about shortages of vital components because they are, often, imported, and supply chains are stretched with skyrocketing global demand.

SpiceJet ties up with Brussels Airport to transport vaccine to Europe

Little surprise then that many countries have requested India either on a government-to-government (G2G) basis or by directly placing orders with the vaccine developers who are manufacturing the doses in India. India is all set to deploy its capacities in vaccine production and supply. Besides the neighbours - barring Pakistan - Brazil, Morocco, Saudi Arabia, Myanmar, Bangladesh, South Africa have made official announcements seeking vaccines from India. According to officials in the Ministry of External Affairs, the government will accord priority to all its South Asian neighbours in vaccine distribution.

As of 2020, Serum Institute is the world's largest vaccine producer by number of doses, producing around 1.5 billion doses of vaccines each year. It puts Serum Institute way ahead of global pharmaceutical majors like GlaxoSmithKline and Sanofi, which manufacture 0.69 billion and 1 billion doses of vaccine respectively, according to the Access to Vaccine Index. Other giants like Merck and Johnson and Johnson produce less than 0.2 billion doses, making them relatively minor vaccine manufacturers.

While Serum Institute is the world’s biggest, India has an embarrassment of riches: it will also access vaccines from Bharat Biotech, an Indian biotechnology company headquartered in Hyderabad, dedicated to drug discovery, drug development and manufacture of vaccines.

The Drugs Controller General of India (DCGI) recently approved Oxford-AstraZeneca’s vaccine, manufactured by Serum Institute in India as Covishield, and Bharat Biotech’s Covaxin for restricted emergency use in the country, even though question marks have been raised by some experts about the approval process of the two vaccines.

After an initial exchange of words, the two Indian companies issued a joint statement saying, “Now that two COVID-19 vaccines have been issued emergency use authorisation (EUA) in India, the focus is on manufacturing, supply, and distribution...Both companies are fully engaged in this activity and consider it our duty to the nation and the world at large to ensure a smooth roll-out of vaccines.”

Mumbai airport to handle over half of SII's Covishield vaccine

The jabs in India could start sooner than in most countries. ``The government will get the vaccines by the middle of January and the private market by April,” says well known epidemiologist, Dr Harinder Singh Ratti.

Little wonder that India is crowing. Prime Minister Narendra Modi has already offered to `protect the world’ with India’s two coronavirus vaccines. ``The world is watching how India conducts the globe’s biggest vaccination programme,” he said, addressing the 16th Pravasi Bhartiya Divas Convention on January 9.

Then the next day at a virtual interaction with Chief Ministers and administrators of Union Territories, Modi told his listeners that four more vaccines are on the way making India the `pharmacy of the world.’

The first beneficiaries of the vaccine would be three crore healthcare and frontline workers, the prime minister said.

COVID-19 vaccine | Bharat Biotech to provide 55 lakh Covaxin doses at Rs 295 per dose

As per the plan, the doses in India would be administered through public and private centres by doctors, dentists, nurses and trained paramedics. Two doses would be given 21 days or 28 days apart, depending upon the vaccine used.

To be sure, a new vaccine means new technology and these stress-laden times, only a follow up of the vaccinated population and their antibodies for a couple of years, would make even vaccine manufacturers wiser.

The other more complex issue of financing the world’s largest inoculation programme remains unclear. Will the Government of India have Rs 80,000 crore available this year and possibly in 2022 to buy and distribute vaccines to everyone in the country, as per an estimate drawn up by the Serum Institute of India? There are no clear answers, but by any yardstick, it is a challenge of epic proportions.

Check Coronavirus News LIVE Updates

Experts are unanimous on one thing though: do not avoid vaccination.

Rajiv Nath, Managing Director - Hindustan Syringes and Medical Devices Ltd, said, “Even though the COVID-19 vaccine is meant primarily for adults, it is surprising that there is apprehension among a section of the population, even though all of us know that the faster the general population, especially the high-risk population gets immunised, the better would be the chances of restoring normalcy.”

That is the bottom line that a majority of vaccine users would do well to understand.
Ranjit Bhushan is an independent journalist and former Nehru Fellow at Jamia Millia University. In a career spanning more than three decades, he has worked with Outlook, The Times of India, The Indian Express, the Press Trust of India, Associated Press, Financial Chronicle, and DNA.
first published: Jan 12, 2021 02:57 pm

stay updated

Get Daily News on your Browser